The Auto-injector's themselves are a solved problem and the device itself did not fail. However, -For over 10 years, It well documented in literature that eve

The Auto-injector's themselves are a solved problem and the device itself did not fail. However, -For over 10 years, It well documented in literature that even in normal BMI women the needle is not long enough to reach muscle. https://www.ncbi.nlm.nih.gov/pubmed?term=15945556 https://www.ncbi.nlm.nih.gov/pubmed?term=15945556 - Prior to around 2003 IM and subcutaneous routes were both listed as valid treatments for anaphylaxis. (See https://www.aafp.org/afp/2003/1001/p1325.html https://www.aafp.org/afp/2003/1001/p1325.html) -Depending on her weight 300mcg may be an appropriate dose for US guidelines (listed at 0.01mg/kg). The listed issues may be from a company taking a 'one-size-fits-most' approach. They also do not update their product with respect to new guidelines and recommendations (new doses, new needle lengths, etc) Possibly to avoid further FDA approval processes? With such large profits and so little competition there is no incentive to innovate/update.